Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Adverum Biotechnologies Inc (ADVM)

Adverum Biotechnologies Inc (ADVM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 112,331
  • Shares Outstanding, K 20,802
  • Annual Sales, $ 3,600 K
  • Annual Income, $ -117,170 K
  • EBIT $ -103 M
  • EBITDA $ -99 M
  • 60-Month Beta 1.14
  • Price/Sales 92.27
  • Price/Cash Flow N/A
  • Price/Book 0.74

Options Overview Details

View History
  • Implied Volatility 76.99% ( -22.68%)
  • Historical Volatility 93.23%
  • IV Percentile 22%
  • IV Rank 19.63%
  • IV High 347.54% on 02/12/25
  • IV Low 10.92% on 06/14/24
  • Put/Call Vol Ratio 2.78
  • Today's Volume 68
  • Volume Avg (30-Day) 32
  • Put/Call OI Ratio 0.07
  • Today's Open Interest 610
  • Open Int (30-Day) 1,356

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -1.31
  • Number of Estimates 4
  • High Estimate -1.05
  • Low Estimate -1.43
  • Prior Year -2.30
  • Growth Rate Est. (year over year) +43.04%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.52 +40.06%
on 02/26/25
5.72 -13.87%
on 03/21/25
+0.73 (+17.38%)
since 02/25/25
3-Month
3.52 +40.06%
on 02/26/25
5.72 -13.87%
on 03/21/25
+0.19 (+4.01%)
since 12/24/24
52-Week
3.52 +40.06%
on 02/26/25
15.16 -67.48%
on 03/27/24
-10.02 (-67.02%)
since 03/25/24

Most Recent Stories

More News
Adverum Biotechnologies Initiates ARTEMIS Phase 3 Study Evaluating Ixo-vec for Wet AMD

ADVM : 4.93 (-8.70%)
Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ADVM : 4.93 (-8.70%)
Adverum Biotechnologies to Participate in the Cowen 45th Annual Health Care Conference

ADVM : 4.93 (-8.70%)
Adverum Biotechnologies to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

ADVM : 4.93 (-8.70%)
Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ADVM : 4.93 (-8.70%)
Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

ADVM : 4.93 (-8.70%)
Adverum Biotechnologies Announces Positive 52-Week LUNA and 4-Year OPTIC Results, and Provides Key Pivotal Program Design Elements

ADVM : 4.93 (-8.70%)
Adverum Biotechnologies to Host Webcast on LUNA Phase 2 and OPTIC Clinical Data for Gene Therapy in Wet AMD on November 18th

Adverum Biotechnologies will host a webcast on November 18th to present key clinical data and program design.Quiver AI SummaryAdverum Biotechnologies, Inc. announced an investor and analyst webcast on...

ADVM : 4.93 (-8.70%)
Adverum Biotechnologies Announces Webcast to Report 52-Week LUNA Phase 2 Clinical Data and 4-Year OPTIC Clinical Data, and to Provide Key Pivotal Program Design Elements

ADVM : 4.93 (-8.70%)
Adverum Biotechnologies: Q3 Earnings Snapshot

Adverum Biotechnologies: Q3 Earnings Snapshot

ADVM : 4.93 (-8.70%)

Business Summary

Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. Adverum develops gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum's core capabilities include clinical development,...

See More

Key Turning Points

3rd Resistance Point 5.83
2nd Resistance Point 5.62
1st Resistance Point 5.28
Last Price 4.93
1st Support Level 4.72
2nd Support Level 4.51
3rd Support Level 4.17

See More

52-Week High 15.16
Fibonacci 61.8% 10.71
Fibonacci 50% 9.34
Fibonacci 38.2% 7.97
Last Price 4.93
52-Week Low 3.52

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar